PathoGenetiX Secures $7,500,000 Series B Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    12 Gill Street Woburn, MA 01801
  • Company Description
    PathoGenetiX has pioneered commercial applications of single molecule DNA, RNA and protein analysis. The company’s innovative technologies address high value unmet needs in bio-security, human diagnostics, and food and drug contaminant monitoring. Addressable segments of these markets where the company’s technology offers compelling advantage approach $4.0 billion.

    U.S. Genomics’ core genomic mapping technologies are capable of identifying and quantitating individual molecules of DNA, RNA and proteins from a complex sample. Large fragments of genomic DNA are extracted from complex samples utilizing a proprietary sample preparation technology. Universal reagent sets are used, and no target amplification or culture is required. DNA detection using these technologies provides genomic species and strain identification, while quantitation of RNAs and proteins can be used to track expression, all within a highly mutiplexable assay format. The core U.S. Genomics genomic mapping tech

  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will allow us to complete development and begin commercializing GSS in the rapidly emerging research market for analysis of microbial populations.
  • M&A Terms
  • Venture Investor
    Ascension Health Ventures
  • Venture Investor
    Excel Venture Management
  • Venture Investor
    CB Health Ventures
  • Venture Investor
    HealthCare Ventures

Trending on Xconomy